NEWLY APPROVED ORAL GLP-1
Foundayo (Orforglipron): A Physician's Complete Guide
Foundayo is a newly approved oral GLP-1 option for chronic weight management — a once-daily pill with no injections and no food or water timing rules. At New Viva MD, Dr. Arpita Surkunte can evaluate whether this option fits your goals and health profile.
Key Facts
Field | Value |
Active ingredient | Orforglipron |
Drug class | Oral small-molecule, non-peptide GLP-1 receptor agonist |
FDA-approved for | Long-term weight management in adults with obesity, or adults with overweight and at least one weight-related comorbid condition |
FDA approval date | April 1, 2026 |
Form / Frequency | Once-daily oral tablet |
Manufacturer | Eli Lilly |
What Is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily, non-peptide small-molecule GLP-1 receptor agonist manufactured by Eli Lilly. It was FDA-approved in April 2026 for long-term weight management in eligible adults.
How Is Foundayo Different From Rybelsus?
Both are oral GLP-1 medications, but Foundayo is a small molecule rather than a peptide, so it can be taken at any time of day without food or water restrictions. Rybelsus must be taken on an empty stomach with specific timing rules.
How Foundayo Works
Foundayo binds to and activates the GLP-1 receptor, helping reduce appetite and caloric intake. Its non-peptide small-molecule design allows it to be taken as a daily oral tablet rather than an injection, and it also delays gastric emptying.
Foundayo vs. Injectable GLP-1 Medications
Foundayo offers a needle-free GLP-1 option for chronic weight management. In the FDA-reviewed obesity trial, adults without type 2 diabetes taking the 17.2 mg dose lost an average of 11.1% of their body weight at 72 weeks, compared with 2.1% with placebo. Foundayo has not been directly compared head-to-head with Wegovy or Zepbound, so percentages from separate trials should be compared cautiously.
Foundayo Dosing Schedule
Foundayo starts at 0.8 mg once daily for at least 30 days, then increases to 2.5 mg once daily for at least 30 days, followed by 5.5 mg once daily for at least 30 days. From there, the dose may increase to 9 mg, 14.5 mg, or 17.2 mg once daily, with at least 30 days at each dose before another increase. Dose changes are based on treatment response and tolerability, and the maximum approved dose is 17.2 mg once daily. Foundayo can be taken with or without food at any time of day.
Common Side Effects of Foundayo
Common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, and abdominal discomfort. Gastrointestinal side effects are often more noticeable while the dose is being increased. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Cost & Insurance
Pricing and coverage vary by insurance plan, and some plans may require prior authorization. Because Foundayo is still a newer medication, coverage policies may continue to change. Manufacturer savings or self-pay options may also be available for eligible patients. Your expected cost should be reviewed before treatment begins.
Can I get Foundayo at New Viva MD?
New Viva MD Weight Loss provides physician-supervised evaluation for Foundayo at our Chandler, Arizona clinic and by telehealth to patients throughout Arizona. Whether Foundayo is prescribed depends on your medical history, diagnosis, and clinical evaluation by Dr. Surkunte — it is not guaranteed. We see patients in person in Chandler and remotely across Arizona, including Gilbert, Mesa, Tempe, Phoenix, Scottsdale, Queen Creek, and Ahwatukee.
Frequently Asked Questions
Is Foundayo the same as Rybelsus?
No — Foundayo is a small molecule with no food/water timing restrictions; Rybelsus is a peptide with strict timing rules.
Is Foundayo FDA-approved?
Yes, approved April 2026 for chronic weight management.
Can Foundayo be taken with food?
Yes — with or without food, any time of day.
Is Foundayo as effective as Zepbound or Wegovy?
Based on currently available data, generally more modest average weight loss than tirzepatide, with limits to cross-trial comparisons.
Can compounding pharmacies make a version of Foundayo?
No — orforglipron is a patented small molecule with no legal compounding pathway.
Does insurance cover Foundayo?
Coverage is still developing since this is a newly approved medication.
Why Choose New Viva MD
Board Certified (ABIM), Diplomate (ABOM) — Dr. Arpita Surkunte personally evaluates every patient
Access to the newest FDA-approved GLP-1 options as they become available
LegitScript-certified — verify us
FDA-approved medications only. No compounded semaglutide, tirzepatide, or orforglipron.
Disclaimer
This page is for educational purposes only and is not medical advice. Prescription medications require evaluation and approval by a licensed provider. Individual results vary. New Viva MD does not offer compounded semaglutide or compounded tirzepatide. Brand names are trademarks of their respective manufacturers; New Viva MD is not affiliated with, endorsed by, or sponsored by these manufacturers. Always consult your healthcare provider before starting, stopping, or changing any medication.